Key result
Intracavitary oxytetracycline resulted in rapidly improving symptoms in all 11 patients with malignant pericardial tamponade, with no pericardial relapse over a median 9-month follow-up.
Why the study?
Does intracavitary oxytetracycline improve symptoms and prevent relapse in patients with malignant pericardial tamponade?
Observational (n=11)
Does intracavitary oxytetracycline improve symptoms and prevent relapse in patients with malignant pericardial tamponade?
Intracavitary oxytetracycline is an effective and well-tolerated treatment for malignant pericardial tamponade, providing durable relief without pericardial relapse.
Answers are grounded in this paper and cite their sources.
May warrant consideration in refractory malignant pericardial tamponade; leaves open efficacy and safety pending prospective trials.
We started a treatment trial for malignant pericardial tamponade with intracavitary oxytetracycline, 500-1,000 mg/day, administered via an indwelling pericardial cannula after extraction of as much pericardial fluid as possible. This procedure was repeated every 24 h for 6 consecutive days or until no more fluid could be drained. Eleven consecutive patients were entered in the study. The responses were obtained by clinical examination, chest roentgenogram and echocardiogram, prior to and after treatment. The primary cancer was located in the breast in 7 patients, in the stomach in 2 patients, and in the lung in 2 patients. In all cases, systemic chemotherapy or hormonal therapy was started after the pericardial tamponade was cured. The mean tetracycline dose per patient was 3,000 mg (range 1,500-6,000). All patients responded to the treatment with rapidly improving symptoms. Response persisted during a median of 9 months coinciding roughly with the median survival because all patients died because of progression of the neoplasm at sites other than the pericardium with no evidence of pericardial relapse. The main concomitant effects were mild local pain during tetracycline instillation in 4 patients, and transient fever (less than 39 degrees C) in 3. These data suggest that intracavitary oxytetracycline is perhaps less toxic and similar by successful as tetracycline hydrochloride in malignant pericardial tamponade.
No takes yet. Share an insight, caveat, or question.
Grau et al. (2009) conducted an observational in Malignant pericardial tamponade (n=11). Intracavitary oxytetracycline was evaluated on Response to treatment (rapidly improving symptoms). Intracavitary oxytetracycline resulted in rapidly improving symptoms in all 11 patients with malignant pericardial tamponade, with no pericardial relapse over a median 9-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: